Results	O
of	O
a	O
Single	O
Institution	O
Experience	O
with	O
Dose	O
-	O
Escalated	O
Chemoradiation	B:C0436307
for	O
Locally	O
Advanced	O
Unresectable	O
Non-Small	O
Cell	I:C0007131
Lung	I:C0007131
Cancer	I:C0007131
.	O

Results	O
of	O
a	O
Single	O
Institution	O
Experience	O
with	O
Dose	O
-	O
Escalated	O
Chemoradiation	O
for	O
Locally	B:C0205276
Advanced	O
Unresectable	O
Non-Small	O
Cell	I:C0007131
Lung	I:C0007131
Cancer	I:C0007131
.	O

Results	O
of	O
a	O
Single	O
Institution	O
Experience	O
with	O
Dose	O
-	O
Escalated	O
Chemoradiation	O
for	O
Locally	O
Advanced	O
Unresectable	B:C1519810
Non-Small	O
Cell	I:C0007131
Lung	I:C0007131
Cancer	I:C0007131
.	O

Results	O
of	O
a	O
Single	O
Institution	O
Experience	O
with	O
Dose	O
-	O
Escalated	O
Chemoradiation	O
for	O
Locally	O
Advanced	O
Unresectable	O
Non-Small	B:C0007131
Cell	I:C0007131
Lung	I:C0007131
Cancer	I:C0007131
.	O

We	O
determined	O
factors	O
associated	O
with	O
morbidity	O
and	O
outcomes	O
of	O
a	O
series	O
of	O
non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
patients	O
treated	O
with	O
dose	O
-	O
escalated	O
chemoradiotherapy	O
at	O
the	O
University	O
of	O
Pittsburgh	O
Lung	O
Cancer	O
Program	O
.	O

We	O
determined	O
factors	O
associated	O
with	O
morbidity	O
and	O
outcomes	O
of	O
a	O
series	O
of	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	B:C0007131
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
patients	O
treated	O
with	O
dose	O
-	O
escalated	O
chemoradiotherapy	O
at	O
the	O
University	O
of	O
Pittsburgh	O
Lung	O
Cancer	O
Program	O
.	O

We	O
determined	O
factors	O
associated	O
with	O
morbidity	O
and	O
outcomes	O
of	O
a	O
series	O
of	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
patients	O
treated	B:C0087111
with	O
dose	O
-	O
escalated	O
chemoradiotherapy	O
at	O
the	O
University	O
of	O
Pittsburgh	O
Lung	O
Cancer	O
Program	O
.	O

We	O
determined	O
factors	O
associated	O
with	O
morbidity	O
and	O
outcomes	O
of	O
a	O
series	O
of	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
patients	O
treated	O
with	O
dose	O
-	O
escalated	O
chemoradiotherapy	B:C0436307
at	O
the	O
University	O
of	O
Pittsburgh	O
Lung	O
Cancer	O
Program	O
.	O

The	O
records	B:C0034869
of	O
170	O
stage	O
III	I:C0278506
NSCLC	I:C0278506
patients	O
treated	O
with	O
definitive	O
intent	O
were	O
retrospectively	O
reviewed	I:C0035363
.	O

The	O
records	O
of	O
170	O
stage	B:C0278506
III	I:C0278506
NSCLC	I:C0278506
patients	O
treated	O
with	O
definitive	O
intent	O
were	O
retrospectively	O
reviewed	I:C0035363
.	O

The	O
records	O
of	O
170	O
stage	O
III	I:C0278506
NSCLC	I:C0278506
patients	O
treated	B:C0087111
with	O
definitive	O
intent	O
were	O
retrospectively	O
reviewed	I:C0035363
.	O

The	O
records	O
of	O
170	O
stage	O
III	I:C0278506
NSCLC	I:C0278506
patients	O
treated	O
with	O
definitive	O
intent	O
were	O
retrospectively	B:C0035363
reviewed	I:C0035363
.	O

All	O
patients	O
received	O
four	B:C2717955
-	I:C2717955
dimensional	I:C2717955
CT	I:C2717955
simulation	I:C2717955
scan	I:C2717955
and	O
had	O
respiratory	O
gating	I:C3877328
if	O
tumor	O
movement	O
exceeded	O
5	O
mm	O
.	O

All	O
patients	O
received	O
four	O
-	I:C2717955
dimensional	I:C2717955
CT	I:C2717955
simulation	I:C2717955
scan	I:C2717955
and	O
had	O
respiratory	B:C3877328
gating	I:C3877328
if	O
tumor	O
movement	O
exceeded	O
5	O
mm	O
.	O

All	O
patients	O
received	O
four	O
-	I:C2717955
dimensional	I:C2717955
CT	I:C2717955
simulation	I:C2717955
scan	I:C2717955
and	O
had	O
respiratory	O
gating	I:C3877328
if	O
tumor	B:C0027651
movement	O
exceeded	O
5	O
mm	O
.	O

All	O
patients	O
received	O
four	O
-	I:C2717955
dimensional	I:C2717955
CT	I:C2717955
simulation	I:C2717955
scan	I:C2717955
and	O
had	O
respiratory	O
gating	I:C3877328
if	O
tumor	O
movement	B:C0026649
exceeded	O
5	O
mm	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
,	O
locoregional	B:C0027643
control	O
(	O
LRC	O
)	O
,	O
and	O
freedom	O
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
(	O
freedom	O
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
)	O
were	O
calculated	O
using	O
log	O
-rank	I:C0392366
and	O
Cox	O
regression	I:C0034980
analysis	I:C0034980
.	O

Overall	O
survival	O
(	O
OS	O
)	O
,	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
and	O
freedom	B:C1513178
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
(	O
freedom	O
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
)	O
were	O
calculated	O
using	O
log	O
-rank	I:C0392366
and	O
Cox	O
regression	I:C0034980
analysis	I:C0034980
.	O

Overall	O
survival	O
(	O
OS	O
)	O
,	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
and	O
freedom	O
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
(	O
freedom	B:C1513178
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
)	O
were	O
calculated	O
using	O
log	O
-rank	I:C0392366
and	O
Cox	O
regression	I:C0034980
analysis	I:C0034980
.	O

Overall	O
survival	O
(	O
OS	O
)	O
,	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
and	O
freedom	O
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
(	O
freedom	O
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
)	O
were	O
calculated	O
using	O
log	B:C0392366
-rank	I:C0392366
and	O
Cox	O
regression	I:C0034980
analysis	I:C0034980
.	O

Overall	O
survival	O
(	O
OS	O
)	O
,	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
and	O
freedom	O
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
(	O
freedom	O
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
)	O
were	O
calculated	O
using	O
log	O
-rank	I:C0392366
and	O
Cox	B:C0034980
regression	I:C0034980
analysis	I:C0034980
.	O

For	O
the	O
present	O
series	O
of	O
patients	O
,	O
median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
was	O
36.6	O
months	O
,	O
median	O
survival	O
27.4	O
months	O
,	O
and	O
the	O
2	O
-	O
and	O
4	O
-	O
year	O
OS	O
was	O
56.0	O
and	O
30.7	O
%	O
,	O
respectively	O
.	O

The	O
4	O
-	O
year	O
LRC	O
and	O
freedom	B:C1513178
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
were	O
43.9	O
and	O
40.7	O
%	O
,	O
respectively	O
.	O

No	O
benefit	O
was	O
associated	O
with	O
irradiation	O
doses	O
above	O
66	O
Gy	O
in	O
OS	O
(	O
p	O
=	O
0.586	O
)	O
,	O
LRC	O
(	O
p	O
=	O
0.440	O
)	O
,	O
or	O
freedom	B:C1513178
from	I:C1513178
distant	I:C1513178
metastasis	I:C1513178
(	O
p	O
=	O
0.230	O
)	O
.	O

On	O
univariate	O
analysis	O
,	O
variables	O
associated	O
with	O
worse	B:C1457868
survival	O
included	O
:	O
clinical	O
stage	O
IIIB	I:C0278984
(	O
p	O
=	O
0.037	O
)	O
,	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
over	O
450	O
cc	O
(	O
p	O
<	O
0.001	O
)	O
,	O
heart	O
V30	O
over	O
40	O
%	O
(	O
p	O
=	O
-	O
0.048	O
)	O
,	O
and	O
esophageal	O
mean	O
dose	O
over	O
20	O
%	O
(	O
p	O
=	O
0.024	O
)	O
,	O
V5	O
(	O
p	O
=	O
-	O
0.015	O
)	O
,	O
and	O
V60	O
(	O
p	O
=	O
-	O
0.011	O
)	O
.	O

On	O
univariate	O
analysis	O
,	O
variables	O
associated	O
with	O
worse	O
survival	O
included	O
:	O
clinical	O
stage	B:C0278984
IIIB	I:C0278984
(	O
p	O
=	O
0.037	O
)	O
,	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
over	O
450	O
cc	O
(	O
p	O
<	O
0.001	O
)	O
,	O
heart	O
V30	O
over	O
40	O
%	O
(	O
p	O
=	O
-	O
0.048	O
)	O
,	O
and	O
esophageal	O
mean	O
dose	O
over	O
20	O
%	O
(	O
p	O
=	O
0.024	O
)	O
,	O
V5	O
(	O
p	O
=	O
-	O
0.015	O
)	O
,	O
and	O
V60	O
(	O
p	O
=	O
-	O
0.011	O
)	O
.	O

On	O
univariate	O
analysis	O
,	O
variables	O
associated	O
with	O
worse	O
survival	O
included	O
:	O
clinical	O
stage	O
IIIB	I:C0278984
(	O
p	O
=	O
0.037	O
)	O
,	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
over	O
450	O
cc	O
(	O
p	O
<	O
0.001	O
)	O
,	O
heart	B:C0018787
V30	O
over	O
40	O
%	O
(	O
p	O
=	O
-	O
0.048	O
)	O
,	O
and	O
esophageal	O
mean	O
dose	O
over	O
20	O
%	O
(	O
p	O
=	O
0.024	O
)	O
,	O
V5	O
(	O
p	O
=	O
-	O
0.015	O
)	O
,	O
and	O
V60	O
(	O
p	O
=	O
-	O
0.011	O
)	O
.	O

On	O
univariate	O
analysis	O
,	O
variables	O
associated	O
with	O
worse	O
survival	O
included	O
:	O
clinical	O
stage	O
IIIB	I:C0278984
(	O
p	O
=	O
0.037	O
)	O
,	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
over	O
450	O
cc	O
(	O
p	O
<	O
0.001	O
)	O
,	O
heart	O
V30	O
over	O
40	O
%	O
(	O
p	O
=	O
-	O
0.048	O
)	O
,	O
and	O
esophageal	B:C1522619
mean	O
dose	O
over	O
20	O
%	O
(	O
p	O
=	O
0.024	O
)	O
,	O
V5	O
(	O
p	O
=	O
-	O
0.015	O
)	O
,	O
and	O
V60	O
(	O
p	O
=	O
-	O
0.011	O
)	O
.	O

On	O
multivariable	O
analysis	O
,	O
PTV	O
above	O
450	O
cc	O
(	O
52.2	O
vs.	O
25.3	O
months	O
,	O
p	O
<	O
0.001	O
)	O
and	O
esophageal	B:C1522619
V60	O
>	O
20	O
%	O
(	O
43.8	O
vs.	O
21.3	O
months	O
,	O
p	O
=	O
-	O
0.01	O
)	O
were	O
associated	O
with	O
lower	O
survival	O
.	O

Grade	B:C0475270
2	I:C0475270
or	O
higher	O
acute	O
lung	O
toxicity	O
and	O
esophagitis	O
were	O
detected	O
in	O
9.5	O
and	O
59.7	O
%	O
,	O
respectively	O
of	O
patients	O
.	O

Grade	O
2	I:C0475270
or	O
higher	O
acute	O
lung	B:C0024109
toxicity	O
and	O
esophagitis	O
were	O
detected	O
in	O
9.5	O
and	O
59.7	O
%	O
,	O
respectively	O
of	O
patients	O
.	O

Grade	O
2	I:C0475270
or	O
higher	O
acute	O
lung	O
toxicity	O
and	O
esophagitis	B:C0014868
were	O
detected	O
in	O
9.5	O
and	O
59.7	O
%	O
,	O
respectively	O
of	O
patients	O
.	O

Grade	O
2	I:C0475270
or	O
higher	O
acute	O
lung	O
toxicity	O
and	O
esophagitis	O
were	O
detected	B:C0442726
in	O
9.5	O
and	O
59.7	O
%	O
,	O
respectively	O
of	O
patients	O
.	O

Grade	B:C0475270
2	I:C0475270
or	O
higher	O
acute	O
lung	O
toxicity	O
was	O
reduced	O
if	O
lung	O
V5	O
was	O
≤	O
65	O
(	O
7.4	O
vs.	O
23.8	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Grade	O
2	I:C0475270
or	O
higher	O
acute	O
lung	B:C0024109
toxicity	O
was	O
reduced	O
if	O
lung	O
V5	O
was	O
≤	O
65	O
(	O
7.4	O
vs.	O
23.8	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Grade	O
2	I:C0475270
or	O
higher	O
acute	O
lung	O
toxicity	O
was	O
reduced	O
if	O
lung	B:C0024109
V5	O
was	O
≤	O
65	O
(	O
7.4	O
vs.	O
23.8	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Grade	B:C0475270
2	I:C0475270
or	O
higher	O
acute	O
esophagitis	O
was	O
reduced	O
if	O
V60	O
≤	O
20	O
%	O
(	O
62	O
vs.	O
81.3	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O

Grade	O
2	I:C0475270
or	O
higher	O
acute	O
esophagitis	B:C0014868
was	O
reduced	O
if	O
V60	O
≤	O
20	O
%	O
(	O
62	O
vs.	O
81.3	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O

The	O
use	O
of	O
intensity	B:C1512814
-	I:C1512814
modulated	I:C1512814
radiation	I:C1512814
therapy	I:C1512814
was	O
more	O
frequent	O
in	O
stage	O
IIIB	I:C0278984
compared	O
to	O
stage	O
IIIA	I:C0278983
patients	O
(	O
56.5	O
vs.	O
39.5	O
%	O
,	O
p	O
=	O
0.048	O
)	O
and	O
was	O
associated	O
with	O
a	O
higher	O
lung	O
V5	O
and	O
V10	O
.	O

The	O
use	O
of	O
intensity	O
-	I:C1512814
modulated	I:C1512814
radiation	I:C1512814
therapy	I:C1512814
was	O
more	O
frequent	O
in	O
stage	B:C0278984
IIIB	I:C0278984
compared	O
to	O
stage	O
IIIA	I:C0278983
patients	O
(	O
56.5	O
vs.	O
39.5	O
%	O
,	O
p	O
=	O
0.048	O
)	O
and	O
was	O
associated	O
with	O
a	O
higher	O
lung	O
V5	O
and	O
V10	O
.	O

The	O
use	O
of	O
intensity	O
-	I:C1512814
modulated	I:C1512814
radiation	I:C1512814
therapy	I:C1512814
was	O
more	O
frequent	O
in	O
stage	O
IIIB	I:C0278984
compared	O
to	O
stage	B:C0278983
IIIA	I:C0278983
patients	O
(	O
56.5	O
vs.	O
39.5	O
%	O
,	O
p	O
=	O
0.048	O
)	O
and	O
was	O
associated	O
with	O
a	O
higher	O
lung	O
V5	O
and	O
V10	O
.	O

The	O
use	O
of	O
intensity	O
-	I:C1512814
modulated	I:C1512814
radiation	I:C1512814
therapy	I:C1512814
was	O
more	O
frequent	O
in	O
stage	O
IIIB	I:C0278984
compared	O
to	O
stage	O
IIIA	I:C0278983
patients	O
(	O
56.5	O
vs.	O
39.5	O
%	O
,	O
p	O
=	O
0.048	O
)	O
and	O
was	O
associated	O
with	O
a	O
higher	O
lung	B:C0024109
V5	O
and	O
V10	O
.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose	O
-	O
escalated	O
chemoradiotherapy	B:C0436307
for	O
unresectable	O
stage	O
IIIA	I:C0278983
and	O
IIIB	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
patients	O
were	O
consistent	O
with	O
other	O
studies	O
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose	O
-	O
escalated	O
chemoradiotherapy	O
for	O
unresectable	B:C1519810
stage	O
IIIA	I:C0278983
and	O
IIIB	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
patients	O
were	O
consistent	O
with	O
other	O
studies	O
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose	O
-	O
escalated	O
chemoradiotherapy	O
for	O
unresectable	O
stage	B:C0278983
IIIA	I:C0278983
and	O
IIIB	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
patients	O
were	O
consistent	O
with	O
other	O
studies	O
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose	O
-	O
escalated	O
chemoradiotherapy	O
for	O
unresectable	O
stage	O
IIIA	I:C0278983
and	O
IIIB	B:C0278984
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
patients	O
were	O
consistent	O
with	O
other	O
studies	O
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose	O
-	O
escalated	O
chemoradiotherapy	O
for	O
unresectable	O
stage	O
IIIA	I:C0278983
and	O
IIIB	O
non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
patients	O
were	O
consistent	O
with	O
other	O
studies	O
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose	O
-	O
escalated	O
chemoradiotherapy	O
for	O
unresectable	O
stage	O
IIIA	I:C0278983
and	O
IIIB	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
patients	O
were	O
consistent	O
with	O
other	O
studies	B:C2603343
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy.	O

Furthermore	O
,	O
maintaining	O
low	O
esophageal	B:C1522619
V60	O
and	O
lung	O
V5	O
were	O
associated	O
with	O
lower	O
morbidity	O
and	O
mortality	O
.	O

Furthermore	O
,	O
maintaining	O
low	O
esophageal	O
V60	O
and	O
lung	B:C0024109
V5	O
were	O
associated	O
with	O
lower	O
morbidity	O
and	O
mortality	O
.	O

